Expression of programmed death-ligand i(pd-l1) in Triple negative breast carcinoma-a cross Sectional study at tertiary care hospital

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression. Programmed death-ligand 1 (PD-L1) plays a role in immune evasion and is a potential therapeutic target. The PD-1/PD-L1 axis allows tumor cells to evade immune surveillance, making PD-L1 expression a promising biomarker for immunotherapy. However, variations in PD-L1 detection methods and scoring criteria impact its clinical interpretation[8]. This study evaluates PD-L1 expression in TNBC using immunohistochemistry and its correlation with clinicopathological parameters. Objectives: To assess immunohistochemical expression of PD-L1 in TNBC utilizing immunohistochemical antibodies and to correlate PDL1 expression with other clinicopathological parameters.